Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
Express Scripts
Medtronic
Colorcon

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR ATOVAQUONE; PROGUANIL HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Atovaquone; Proguanil Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00084227 ↗ Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America Completed Pfizer Phase 2/Phase 3 2004-07-01 The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
NCT00149383 ↗ Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria Completed McLaughlin-Rotman Center for Global Health, University of Toronto Phase 1/Phase 2 2004-12-01 The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
NCT00149383 ↗ Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria Completed Mahidol University Phase 1/Phase 2 2004-12-01 The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
NCT00379821 ↗ Chloroquine Alone or in Combination for Malaria in Children in Malawi Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2007-02-01 Malaria is a sickness caused by a germ that can get into a person's body when a mosquito bites them. It can cause fever, headache, body aches and weakness. It can even cause death, especially in children. When malaria is treated with the appropriate medicine(s), it can be cured completely. The purpose of this study is to find out if it is better to use chloroquine alone or in combination with another drug to most effectively treat malaria. About 640 children with malaria, aged 6 months to 5 years of age, from the Blantyre Malaria Project Research Clinic at the Ndirande Health Center in Malawi will be in the study. They will be treated with either chloroquine alone or a combination of chloroquine plus another medication (azithromycin or artesunate or atovaquone-proguanil) every time they get malaria for a year. Blood samples will be collected and tested at least every 4 weeks. Participants will be involved in the study for 1 year.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atovaquone; Proguanil Hydrochloride

Condition Name

Condition Name for Atovaquone; Proguanil Hydrochloride
Intervention Trials
Malaria 12
Controlled Human Malaria Infection 2
Falciparum 2
Falciparum Malaria 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atovaquone; Proguanil Hydrochloride
Intervention Trials
Malaria 21
Malaria, Falciparum 7
Infections 2
Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atovaquone; Proguanil Hydrochloride

Trials by Country

Trials by Country for Atovaquone; Proguanil Hydrochloride
Location Trials
Netherlands 6
Thailand 3
United States 3
Cambodia 2
Vietnam 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atovaquone; Proguanil Hydrochloride
Location Trials
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atovaquone; Proguanil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Atovaquone; Proguanil Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atovaquone; Proguanil Hydrochloride
Clinical Trial Phase Trials
Completed 17
Terminated 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atovaquone; Proguanil Hydrochloride

Sponsor Name

Sponsor Name for Atovaquone; Proguanil Hydrochloride
Sponsor Trials
Radboud University 4
Medicines for Malaria Venture 3
The PATH Malaria Vaccine Initiative (MVI) 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atovaquone; Proguanil Hydrochloride
Sponsor Trials
Other 35
Industry 9
U.S. Fed 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Johnson and Johnson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.